CTX112 donor-derived CAR-T study including progressive MS
Published by MyelinWatch:
CTX112 donor-derived CAR-T study including progressive MS · The trial plans to test donor-derived CD19 CAR-T cells in adults with refractory neurological autoimmune disease, including progressive MS.
What is being studied
The trial plans to test donor-derived CD19 CAR-T cells in adults with refractory neurological autoimmune disease, including progressive MS.
Research stage
Phase 1/2 study in people — safety and possible benefit
The study is not yet accepting participants.
What we know so far
The combined Phase 1/2 protocol is registered but not yet accepting participants. The registry does not establish actual enrolment or exposure and has no posted results.
What this means for patients today
This is not an available MS treatment. The study is not yet accepting participants; no Greek site or individual eligibility is established.
- Treatment or approach
- CTX112 donor-derived CAR-T study including progressive MS
- Where the study is running
- No study location is listed in this record; Greek access is unverified.
- Published by MyelinWatch
- Last substantive MyelinWatch update